LIMP-2 deficiency-associated glycolipid abnormalities in mice
View abstract on PubMed
Summary
This summary is machine-generated.Lysosomal integral membrane protein type 2 (LIMP-2) deficiency reduces glucocerebrosidase (GCase) levels, causing distinct symptoms from Gaucher disease. LIMP-2 deficiency prevents glucosylceramide accumulation by altering metabolite levels.
Area Of Science
- Cell Biology
- Biochemistry
- Genetics
Background
- Glucocerebrosidase (GCase) degrades glucosylceramide (GlcCer) in lysosomes.
- GCase deficiency causes Gaucher disease (GD), characterized by organ enlargement.
- Lysosomal integral membrane protein type 2 (LIMP-2) facilitates GCase transport to lysosomes.
Purpose Of The Study
- Investigate the differing pathologies of GD and LIMP-2 deficiency (Action Myoclonic Renal Failure Syndrome - AMRF).
- Determine the impact of LIMP-2 deficiency on lysosomal enzymes and glycosphingolipid metabolism.
Main Methods
- Analysis of lysosomal enzymes and GCase activity in Limp2-/- mice tissues and leukocytes.
- Measurement of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph), and glucosylated cholesterol (GlcChol) levels.
- Biochemical analysis of isolated lysosomes and tritosomes from Limp2-/- hepatocytes.
Main Results
- Limp2-/- mice exhibit variable GCase deficiency but not GD.
- GCase deficiency in tissues correlates with increased GlcSph and GlcChol, not GlcCer.
- Lysosomes and tritosomes from Limp2-/- hepatocytes show elevated GlcSph and GlcChol.
Conclusions
- LIMP-2 plays a crucial role in maintaining glycosphingolipid homeostasis.
- LIMP-2 deficiency prevents GlcCer accumulation despite reduced GCase levels.
- The distinct metabolite profile in LIMP-2 deficiency explains its unique symptomatology compared to GD.

